Imagine a camera that can see deep inside your body without needing surgery or radiation. It uses light and sound waves to map out things like inflammation and oxygen levels in real-time. It's like giving doctors a high-definition window into living tissue to see exactly how a disease is progressing.
Current gold-standard diagnostics for deep-tissue diseases are often too expensive, too invasive, or lack the quantitative accuracy needed for routine clinical use in smaller clinics.
The MSOT Frontier system, a smaller and cheaper-to-manufacture version of Multispectral Optoacoustic Tomography imaging hardware.
If you are a diagnostic equipment provider dealing with high manufacturing costs for deep-tissue scanners — this project developed the MSOT Frontier system that lowers production costs and reduces device size. This makes the technology viable for smaller clinics.
If you are a clinic dealing with invasive gold-standard tests for neuromuscular diseases — this project developed a non-invasive imaging tool that monitors treatment response. This reduces the patient burden and improves decision-making for prognosis.
If you are a vascular center dealing with a lack of quantitative measurements for arterial health — this project developed the MSOT Frontier system that visualizes tissue oxygenation. This allows for better-informed treatment choices and improved patient outcomes.
The project focused on redesigning key components of the MSOT system specifically to lower the cost of manufacturing. This aims to make the device commercially viable for the broad clinical market.
The project transitioned the system from a research environment to a version optimized for routine clinical imaging. It specifically addressed device size and manufacturing costs to enable deployment.
Based on available project data, the technology is developed by iThera Medical GmbH, but specific licensing terms are not detailed in the report.
The project included a core objective to strategize for clinical validation to demonstrate the technology's clinical value for routine diagnostics.
The project ran from 2022-04-01 to 2024-03-31 to translate the research novelty into a market-ready diagnostic tool.
The project is led by a single partner, iThera Medical GmbH, a German SME. This 100% industry-led structure indicates a strong focus on commercialization and direct market entry rather than academic exploration.
Contact iThera Medical GmbH in Germany for commercial inquiries regarding MSOT Frontier.
Contact us to find similar deep-tissue imaging opportunities.
